EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Marco Strecker iD, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos und 5 weitere

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.70129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Marco Strecker und 16 weiteren Autor:innen. Beteiligte Einrichtung: Molecular and Experimental Surgery, Clinic for Visceral-, General, Vascular and Transplantation Surgery, University Medicine Magdeburg, Otto-von Guer…. Hauptthemen laut MEDLINE: Amino Acid Transport System y+, Colonic Neoplasms, Pharmacogenetics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) represents the third leading cause of cancer‐related deaths. Integrating cellular and molecular data from individual patients has become valuable for diagnosis, prognosis, and treatment selection. Here, we present a comparative mRNA‐seq analysis of tissue samples from 32 CRC patients, pairing tumors with adjacent healthy tissues. Differential expression gene (DEG) analysis revealed dysregulated metabolic programs. We focused on the impact of overexpressed SLC7A11 (xCT) and SLC3A2, which compose the cystine/glutamate transporter (Xc‐) system. To assess the oncogenic potential of the Xc‐ system, we analyzed gene perturbations from CRISPR screens across various cell types and used functional assays in five primary patient‐derived organoid models. We identified a previously uncharacterized cell surface protein signature predicting chemotherapy resistance and highlighted the causality and potential of pharmacological blockage of ferroptosis as a promising avenue for cancer therapy. Redox homeostasis, ion/amino acid transporters, and regulators of neuronal survival and differentiation were pathways associated with these co‐dependent genes in patient specimens. This study highlights several potential clinical targets for CRC therapy and promotes the use of patient‐derived organoids oids to functionally validate in silico predictions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amino Acid Transport System y+Colonic NeoplasmsPharmacogeneticsHumansGene Expression Regulation, NeoplasticOrganoidsFemaleCell Line, TumorMaleFerroptosisMolecular Targeted TherapyFusion Regulatory Protein 1, Heavy Chain

Stichwörter der Autor:innen

chemotherapy resistanceferroptosispatient‐derived organoidstumor metabolismxCT

Substanzen

Amino Acid Transport System y+SLC7A11 protein, humanSLC3A2 protein, humanFusion Regulatory Protein 1, Heavy Chain

Autor:innen und Institutionen

  • Molecular and Experimental Surgery, Clinic for Visceral-, General, Vascular and Transplantation Surgery, University Medicine Magdeburg, Otto-von Guericke University Magdeburg, Magdeburg, Germany.
  • Department of Biological Chemistry, Faculty of Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Clinic for Hematology and Oncology, University Medicine Magdeburg, Otto-von Guericke University Magdeburg, Magdeburg, Germany.
  • Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • Faculty of Medicine, The Hebrew University of Jerusalem, Israel.
  • Institute for Pathology, University Medicine Magdeburg, Otto-von Guericke University Magdeburg, Magdeburg, Germany.

ORCID-Profile: Marco Strecker, Ulf D Kahlert

Zitieren

APA

Strecker, M., Zohar, K., Böttcher, M., Wartmann, T., Freudenstein, H., Doelling, M., Andric, M., Shi, W., Kakhlon, O., Hippe, K., Jahnke, B., Mougiakakos, D., Baenke, F., Stange, D., Croner, R. S., Linial, M., & Kahlert, U. D. (2025). Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity. Molecular Oncology. https://doi.org/10.1002/1878-0261.70129

Vancouver

Strecker M, Zohar K, Böttcher M, Wartmann T, Freudenstein H, Doelling M, et al. Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity. Molecular Oncology. 2025. doi:10.1002/1878-0261.70129

BibTeX
@article{Strecker2025,
  author = {Strecker, Marco and Zohar, Keren and Böttcher, Martin and Wartmann, Thomas and Freudenstein, Henry and Doelling, Maximilian and Andric, Mihailo and Shi, Wenjie and Kakhlon, Or and Hippe, Katrin and Jahnke, Beatrix and Mougiakakos, Dimitrios and Baenke, Franziska and Stange, Daniel and Croner, Roland S and Linial, Michal and Kahlert, Ulf D},
  title = {Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.70129}
}
Kostenlos starten →